NASDAQ-100

Alnylam Pharmaceuticals (ALNY) — 10-Year DCF Projection Model

Free stock research tool. Build a 10-year revenue, earnings (EPS), and free cash flow forecast for Alnylam Pharmaceuticals (ALNY) stock, a company in the Health Care sector. Pulls audited SEC EDGAR XBRL financials, triangulates Wall Street analyst consensus across Yahoo Finance, NASDAQ, and StockAnalysis, and overlays AI-clustered news + social event probabilities directly onto projected EPS. For equity research — not personal budgeting or accounting.

Build ALNY projection model →Browse all stocks

Alnylam Pharmaceuticals at a glance

Ticker
ALNY
Company
Alnylam Pharmaceuticals
Sector
Health Care
Index membership
NASDAQ-100

What you'll see in your ALNY model

  • 10 years of audited historical financials for Alnylam Pharmaceuticals, sourced directly from the SEC's EDGAR XBRL filings (10-K and 10-Q).
  • Triangulated Wall Street consensus for ALNY's forward revenue, EBITDA, and EPS across Yahoo Finance, NASDAQ, and StockAnalysis with cross-source dispersion (σ).
  • AI Event Factors: top-10 news/social themes for ALNY with probability sliders and live EPS impact.
  • Sensitivity tables and Excel export for every assumption.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (NYSE/NASDAQ: ALNY). The company operates in the Health Care sector and is a constituent of the NASDAQ-100. Our projection model builds a clean discounted-cash-flow view of Alnylam Pharmaceuticals in roughly five seconds and lets you adjust every assumption to test your own thesis.